












Development of IKZF2 molecular glue degrader

Korea Research Institute of Chemical Technology

Disease Area	Oncology																			
Product Type	Molecular Glue Degradar (MGD)																			
Indication	Solid Tumor																			
Target	IKZF2 (Helios)																			
Mechanism of Action	Degradation of IKZF2 mediated by CRBN E3 ligase																			
Competitiveness	<ul style="list-style-type: none">• Best-in-Class• Highly potent and selective IKZF2 degrader• Very good PK and anti-tumor efficacy in syngeneic mouse model• Competitor : Plexium (PLX-4107, Phase I), BMS (Phase I), Novartis (DKY709, Phase I, Discontinued)																			
Development Stage	Lead																			
Route of Administration	Oral (PO)																			
Key Data	<div><div><div>Degradation by WB (Jurkat, 6hr treatment)</div><div><div>DKY709</div><div></div><div>IKZF2 IKZF1 IKZF3 Actin</div></div><div><div>KMG-1694</div><div></div><div>IKZF2 IKZF1 IKZF3 Actin</div></div></div></div> <div><div>Quantitative analysis (WB)</div><table><tr><th rowspan="2">Jurkat 6hr treatment</th><th colspan="4">DC50 (nM), [Dmax (%)]</th></tr><tr><th>IKZF2</th><th>IKZF1</th><th>IKZF3</th><th>GSPT1</th></tr><tr><td>DKY709</td><td>1640 [57]</td><td>56700 [37.6]</td><td>> 10000</td><td>> 10000</td></tr><tr><td>KMG-1694</td><td>0.19 [100]</td><td>21200 [41.6]</td><td>> 10000</td><td>> 10000</td></tr></table></div> <div><div>HiBiT-SALL4 (6hr)</div><div></div></div> <div><div>Time-dependent experiment</div><div><div>DKY709 (1 μM)</div><div></div><div>IKZF2 Actin</div></div><div><div>KMG-1694 (0.1 μM)</div><div></div><div>IKZF2 Actin</div></div></div> <div><div>Duration (with degrader)</div><div><div>DKY709 (1 μM)</div><div></div><div>IKZF2 Actin</div></div><div><div>KMG-1694 (0.1 μM)</div><div></div><div>IKZF2 Actin</div></div></div> <div><div>Duration (removal of degrader after 6 hr)</div><div><div>DKY709 (1 μM)</div><div></div><div>IKZF2 Actin</div></div><div><div>KMG-1694 (0.1 μM)</div><div></div><div>IKZF2 Actin</div></div></div> <div><div>IL-2 ELISA results</div><div></div></div> <div><div>Global proteomic analysis (Jurkat, 6 hr)</div><div></div></div>	Jurkat 6hr treatment	DC50 (nM), [Dmax (%)]				IKZF2	IKZF1	IKZF3	GSPT1	DKY709	1640 [57]	56700 [37.6]	> 10000	> 10000	KMG-1694	0.19 [100]	21200 [41.6]	> 10000	> 10000
Jurkat 6hr treatment	DC50 (nM), [Dmax (%)]																			
	IKZF2	IKZF1	IKZF3	GSPT1																
DKY709	1640 [57]	56700 [37.6]	> 10000	> 10000																
KMG-1694	0.19 [100]	21200 [41.6]	> 10000	> 10000																